No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 346 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 Severe Side Effects of Cancer Treatment Are More Common in Women... March 15, 2022 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist February 23, 2021 Load more HOT NEWS Man Gets His First Haircut In 15 Years To Join The... Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... El cáncer en mi comunidad: Cómo acceden las personas con cáncer... Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show
